Heparin induced thrombocytopenia (HIT)
ICD-10 D75.82 is a billable code used to indicate a diagnosis of heparin induced thrombocytopenia (hit).
Heparin-induced thrombocytopenia (HIT) is a serious immune-mediated adverse reaction to heparin, characterized by a decrease in platelet count and an increased risk of thrombosis. HIT typically occurs 5 to 14 days after the initiation of heparin therapy, although it can occur sooner in patients with prior exposure to heparin. The condition is classified into two types: Type I, which is a non-immune response and usually mild, and Type II, which is the more severe immune-mediated form. In Type II HIT, antibodies form against the heparin-platelet factor 4 complex, leading to platelet activation, thrombocytopenia, and a paradoxical increase in thrombotic events. Clinically, patients may present with symptoms of thrombosis, such as deep vein thrombosis or pulmonary embolism, and may also experience skin necrosis at the injection site. Diagnosis is confirmed through clinical assessment and laboratory tests, including platelet counts and specific antibody assays. Management involves immediate cessation of heparin and the initiation of alternative anticoagulation therapy.
Detailed lab results, clinical notes on platelet counts, and treatment plans.
Patients presenting with thrombocytopenia after heparin therapy, requiring management of HIT.
Documentation must clearly differentiate between HIT types and include any thrombotic events.
Comprehensive patient history, medication lists, and clinical assessments.
Management of hospitalized patients receiving heparin who develop thrombocytopenia.
Ensure that the clinical context supports the diagnosis of HIT and includes follow-up plans.
Used to monitor platelet levels in patients suspected of HIT.
Document the reason for the platelet count and any relevant clinical findings.
Hematology specialists should ensure that the clinical context supports the need for testing.
Type I HIT is a non-immune response that usually resolves without treatment, while Type II HIT is an immune-mediated condition that can lead to serious complications and requires immediate management.
